Amicidin-β topical solution - 15 mL + Amicidin-β topical solution - 50 mL + Standard of Care (SOC)

About Amicidin-β topical solution - 15 mL + Amicidin-β topical solution - 50 mL + Standard of Care (SOC)

Amicidin-β topical solution - 15 mL + Amicidin-β topical solution - 50 mL + Standard of Care (SOC) is a phase 1 stage product being developed by Novo Nordisk for Surgical Wound Infection. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07379684. Target conditions include Surgical Wound Infection, Traumatic Wound Infection.

Hype Score Breakdown